MorphoSys AG Revenue 2018-2021 | MOR

MorphoSys AG revenue from 2018 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
MorphoSys AG Annual Revenue
(Millions of US $)
2020 $374
2019 $80
2018 $90
2017 $75
MorphoSys AG Quarterly Revenue
(Millions of US $)
2021-06-30 $46
2021-03-31 $57
2020-12-31 $51
2020-09-30 $26
2020-06-30 $20
2020-03-31 $277
2019-12-31 $12
2019-09-30 $14
2019-06-30 $39
2019-03-31 $15
2018-12-31 $13
2018-09-30 $64
2018-06-30 $10
2018-03-31 $3
2017-12-31 $33
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.560B $0.374B
MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43